In Phase C, participants will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will receive ABBV-744 and ruxolitinib. Participants will acquire treatment until eventually disease progression or the participants are unable to tolerate the study drugs. In general, our recent work highlights the potential utilization of ARV-825 in combination https://abbv-744-brd4-inhibitor-c13467.mdkblog.com/37840828/top-latest-five-brd4-targeted-therapy-abbv-744-clinical-data-urban-news